What is Recombinetics?
Recombinetics is at the forefront of animal gene editing, developing cutting-edge solutions tailored for biomedical research, regenerative medicine, and the agricultural sector. The company's core expertise lies in creating custom gene-edited swine models, which are instrumental in enhancing preclinical research efficacy and reducing the dependency on nonhuman primates. Recombinetics is committed to driving biomedical innovation through its integrity-driven services and products, serving clients across the healthcare and agricultural industries with a focus on improving animal welfare and promoting sustainable practices.
How much funding has Recombinetics raised?
Recombinetics has raised a total of $69.8M across 10 funding rounds:
Private Equity
$540K
Private Equity
$5.7M
Multiple Rounds
$19.3M
Debt
$7M
Private Equity
$2.1M
Series A
$34M
Debt
$350K
Debt
$766K
Private Equity (2014): $540K, investors not publicly disclosed
Private Equity (2015): $5.7M, investors not publicly disclosed
Private Equity (2016): $630K, investors not publicly disclosed
Unspecified (2016): $7.7M, investors not publicly disclosed
Private Equity (2016): $11M, investors not publicly disclosed
Debt (2017): $7M, investors not publicly disclosed
Private Equity (2017): $2.1M, investors not publicly disclosed
Series A (2018): $34M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Debt (2021): $766K backed by PPP
What's next for Recombinetics?
With a significant enterprise-level funding context and a recent strategic investment, Recombinetics is well-positioned for accelerated growth and expanded market penetration. The company's focus on developing advanced gene-edited animal models for critical research applications suggests a strategic trajectory towards becoming a key player in preclinical studies and potentially in therapeutic development. Future endeavors will likely involve scaling operations, further refining their gene-editing technologies, and forging new partnerships within the biomedical and agricultural ecosystems to capitalize on the increasing demand for innovative animal health and research solutions.
See full Recombinetics company page
